Brief: Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
08/11/2017 02:36
Nov 8 (Reuters) - Kaken Pharmaceutical Co Ltd 4521.T
* Says co signed an exclusive distribution agreement with
Tai Tien
Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of
Mitsubishi Tanabe Pharma Corporation 4508.T , for the topical
formulation for Onychomycosis "Clenafin/Jublia" (product) in
Taiwan
* According to the agreement, co grants to Tai Tien the
exclusive
right for sales of the product in Taiwan and Tai Tien expects to
launch the product in 2018
Source text in Japanese: https://goo.gl/qWdjFh
Further company coverage: 4521.T 4508.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: Tingting.liu@thomsonreuters.com@reuters.net))